Figures & data
Figure 1. The structure of vernodalinol.
Figure 2. The flow chart of vernodalinol isolation.
Table 1. 1H and 13C NMR (500 and 125 MHz, methanol-d) data for vernodalinol.
Figure 3. Selected heteronuclear multiple-bond correlations (HMBC) for vernodalinol.
Figure 4. The conformation of cyclohexane ring for vernodalinol and the key correlation spectroscopy (COSY) correlation.
Figure 5. Crystal structure of vernodalinol.
Figure 6. Inhibition of DNA synthesis by vernodalinol. Cells at the logarithmic growth phase were treated with either 25 or 50 μg/mL for 18 h before addition of 1 μCi/mL [3H]-thymidine for 4 h. Each data point represents the mean of three independent experiments done in duplicates (n = 3). Exposure of vernodalinol inhibited DNA synthesis in both concentration- and solvent-dependent fashion. Vernodalinol at 25 μg/mL inhibited DNA synthesis by ∼34% (P-value <0.025), while at 50 μg/mL vernodalinol inhibited DNA synthesis by 40% (P-value <0.025).
![Figure 6. Inhibition of DNA synthesis by vernodalinol. Cells at the logarithmic growth phase were treated with either 25 or 50 μg/mL for 18 h before addition of 1 μCi/mL [3H]-thymidine for 4 h. Each data point represents the mean of three independent experiments done in duplicates (n = 3). Exposure of vernodalinol inhibited DNA synthesis in both concentration- and solvent-dependent fashion. Vernodalinol at 25 μg/mL inhibited DNA synthesis by ∼34% (P-value <0.025), while at 50 μg/mL vernodalinol inhibited DNA synthesis by 40% (P-value <0.025).](/cms/asset/ea9edd18-f055-49aa-ab2d-a1be5615bf66/iphb_a_523429_f0006_b.gif)